Lucid (LCID)

Search documents
Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event
Prnewswire· 2024-08-08 12:31
Event held at Fort Worth Fire Department in partnership with Front Line Mobile Health NEW YORK, Aug. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the successful completion of a #CheckYourFoodTube Precancer Testing Event in partnership with the Fort Worth Fire Department (FWFD) and Front Line Mobile Health ("Front Line"), a comprehensive m ...
Amazing News for Lucid Investors
The Motley Fool· 2024-08-08 08:33
Investors who stuck with Lucid through a bumpy year are now rewarded with some momentum and good news. It's been a bumpy ride recently for start-up electric vehicle (EV) makers. Fisker has been overtaken by bankruptcy, and many start-ups are dealing with horrendous cash burn, a lack of affordable EV options for mainstream consumers to adopt, and slowing EV sales growth in the U.S. market. It's been especially difficult for Lucid Group (LCID -5.83%) because its Air sedan, by most accounts a fantastic EV, has ...
Lucid Group Stock Gains Traction, But Its Stock Price Won't
MarketBeat· 2024-08-07 12:00
Lucid Group NASDAQ: LCID had a better-than-expected quarter, with production and deliveries rising, revenue outpacing consensus estimates, and the balance sheet capitalized. Still, its stock price is unlikely to move significantly higher. This cash-intensive EV OEM startup is still burning cash, slowly eating itself to death, and dilution is a significant headwind for shareholders. Additionally, the capital structure, threat of dilution and failure have the short-interest running near 30%, a dead weight for ...
Lucid Stock Rises After $1.5 Billion Investment for New SUV, Saudi Factory
Investopedia· 2024-08-06 18:46
Key Takeaways Electric vehicle (EV) maker Lucid Group announced $1.5 billion in funding commitments from its largest shareholder, a Saudi investment fund affiliate. The funding is expected to be used to build an EV factory in Saudi Arabia and to ramp up production of the company's Gravity SUV. Lucid posted a wider-than-expected second-quarter loss late Monday. Lucid Group (LCID) shares rose Tuesday after the company posted second-quarter results after the bell Monday and announced $1.5 billion in funding co ...
Lucid Group Analysts Break Down Q2 Earnings, $1.5B Saudi Financing For EV Stock: 'We See This Capital Raise As Significant'
Benzinga· 2024-08-06 16:29
Electric vehicle Lucid Group LCID gets praise from analysts for its updated financing, vehicle launch timeline and superior technology after reporting second-quarter financial results. The Lucid Analysts: Needham analyst Chris Pierce reiterated a Hold rating and has no price target on the stock. Cantor Fitzgerlad analyst Andres Sheppard upgraded shares from Underweight to Neutral and reiterated a $4 price target. RBC Capital Markets analyst Tom Narayan reiterated a Sector Perform rating and $3 price target. ...
Cantor Fitzgerald Just Upgraded Lucid (LCID) Stock
Investor Place· 2024-08-06 16:12
Lucid (NASDAQ:LCID) continues to receive support from Public Investment Fund (PIF) affiliate Ayar Third Investment Company, as the electric vehicle (EV) company announced this morning that the firm had agreed to provide it with $1.5 billion of capital. Lucid also reported its second-quarter earnings. $750 million of the $1.5 billion will be in the form of convertible preferred stock, while the remaining $750 million consists of an unsecured delayed draw term loan facility. As a result of the funding, Lucid ...
Lucid News: Why LCID Stock Is Making Bullish Headlines Today
Investor Place· 2024-08-06 15:53
Lucid (NASDAQ:LCID) stock is catching a bid after the electric vehicle (EV) company reported its secondquarter earnings. Lucid also announced that Ayar Third Investment Company, an affiliate of Saudi Arabia's Public Investment Fund (PIF), has agreed to an investment of $1.5 billion. Ayar is already the largest shareholder of LCID stock. The investment includes the purchase of $750 million of convertible preferred stock through a private placement and another $750 million through an unsecured delayed draw te ...
Lucid: Another Large Capital Raise
Seeking Alpha· 2024-08-06 14:40
117 11 I Ti F H 7 H 1 r -1.8 H H 1 I ri F Th H th 1 15 1 T n PM Images After the bell on Monday, we received second quarter results from Lucid (NASDAQ:LCID). The luxury electric vehicle maker has been one of the most disappointing names in the market since going public over the years, as it has continually missed growth targets. The company's inability to grow as fast as hoped has resulted in large losses and cash burn, with a repeat of that in Q2 requiring Lucid to again get assistance from an affiliate of ...
Lucid Stock Bounces on Earnings, $1.5 Billion Investment
Schaeffers Investment Research· 2024-08-06 14:34
Lucid Group Inc (NASDAQ:LCID) stock is 5.5% higher to trade at $3.17 at last check and seeing unusually high options volume after earnings. In addition to a second-quarter revenue beat and reaffirmed outlook of 9,000 EVs produced in 2024, the electric vehicle (EV) name received a $1.5 billion investment from Saudi Arabia's Public Investment Fund to accelerate production of a new SUV. Still deep in penny stock territory, Lucid Group stock is also down over 50% over the last 12 months. Plus, the 280-day movin ...
Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing
Prnewswire· 2024-08-06 12:15
Real-world data confirms utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy NEW YORK, Aug. 6, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the release of new real-world data from its ENVET-BE study supporting the clinical utility of the EsoGuard® Esophageal DNA test as a no ...